Outcome of Delayed Cholecystectomy after Percutaneous Cholecystostomy for Acute Cholecystitis.

BACKGROUND: Recent studies have suggested that urgent cholecystectomy is the preferred treatment for acute cholecystitis. However, initial conservative treatment followed by delayed elective surgery is still common practice in many medical centers. OBJECTIVES: To determine the effect of percutaneous cholecystostomy on surgical outcome in patients undergoing delayed elective cholecystectomy. METHODS: We conducted a retrospective analysis of all patients admitted to our medical center with acute cholecystitis who were treated by conservative treatment followed by delayed cholecystectomy between 2004 and 2013. Logistic regression was calculated to assess the association of percutaneous cholecystostomy with patient characteristics, planned surgical procedure, and the clinical and surgical outcomes. RESULTS: We identified 370 patients. Of these, 134 patients (36%) underwent cholecystostomy during the conservative treatment period. Patients who underwent cholecystostomy were older and at higher risk for surgery. Laparoscopic cholecystectomy was offered to 92% of all patients, yet assignment to the open surgical approach was more common in the cholecystostomy group (16% vs. 3%). Cholecystostomy was associated with significantly higher conversion rates to open approach (26% vs. 13%) but was not associated with longer operative time, hemorrhage, surgical infections, or bile duct or organ injuries. CONCLUSIONS: Treatment with cholecystostomy is associated with higher conversion rates but does not include other major operative-related complications or poorer clinical outcome.

Early Outcomes and Mid-Term Safety of One Anastomosis Gastric Bypass Are Comparable with Roux-en-Y Gastric Bypass: a Single Center Experience.

BACKGROUND: The use of one anastomosis gastric bypass (OAGB) has increased in recent years. However, the efficacy and safety outcomes of this procedure remain under debate. Here, we compare our early outcome and mid-term safety of OAGB with primary Roux-en-Y gastric bypass (RYGB). METHODS: This was a retrospective study using computerized electronic medical records data of patients who underwent RYGB or OAGB as a primary procedure from February 2012 to February 2019 in our bariatric center. Data collected included demographics, weight-outcomes, adverse events, hospital readmission, reoperation rates, and mortality following both procedures. RESULTS: A total of 314 patients were included (132 RYGB and 182 OAGB). Operative time and costs were significantly lower for OAGB (80 vs. 125 min, p<0.01 and 2018.8 vs. 2912.3 USD, p < 0.01, respectively), but length of hospital stay was longer (4.06 ± 0.67 days vs. 3.58 ± 0.79, p < 0.0001). At 12 months post-surgery, the percentage of excess body mass index loss was comparable between the two groups, but the change in body mass index (BMI) was significantly higher in the OAGB group. Early (< 30 days) and late (> 30 days) surgical adverse events were also similar between the two groups. CONCLUSION: Comparable short- and mid-term outcomes and adverse events are found for primary OAGB and RYGB. OAGB is not inferior to RYGB as a primary bariatric procedure for the treatment of obesity.

The Impact of Ethnic Differences Between Israeli-Jews and Israeli-Arabs on Post-bariatric Surgery Weight Loss: a Prospective Cohort Analysis.

Previous studies from different countries have shown that ethnic diversity may have an important effect on clinical outcome following bariatric procedures. Israel has an ethnic diverse population but there is limited information about this effect on surgery outcome. We carried out a 3-year institutional, prospective comparative data collection study among Jewish and Arab patients in Israel undergoing primary bariatric surgery. Percent of total weight loss (%TWL) and change in body mass index (BMI) were assessed. The results revealed no difference between Arab and Jewish participants in %TWL nor BMI change. Differences in absolute BMI values were all accounted for by the initial between-group difference in the pre-operative BMI. Comorbidity resolution at 1 year post-surgery was not significantly different between the groups.

Laparoscopic Conversion of Roux-en-Y Gastric Bypass to Sleeve Gastrectomy for Postprandial Hyperinsulinemic Hypoglycemia.

INTRODUCTION: Roux-en-Y gastric bypass (RYGB) has proven to be a safe and effective treatment for obesity and its related comorbidities. However, RYGB may lead to uncommon, but occasionally difficult to treat complications such as postprandial hyperinsulinemic hypoglycemia (PHH) [1]. PHH is a condition characterized by hypoglycemic symptoms occurring 1-3 h after a meal, accompanied by low plasma glucose levels, typically preceded by a rise in both glucose and insulin concentrations [2]. The incidence of PHH is unknown and is probably underdiagnosed, as many patients are asymptomatic. The goal for the treatment of PHH after RYGB are to moderate postprandial fluctuations in plasma glucose, reduce insulin secretion, and ultimately reduce hypoglycemia [3]. Therapeutic options can be divided into medical and surgical. In cases of refractory patients, surgical treatment options include partial or total pancreatectomy, or a RYGB reversal procedure accompanied by gastric pouch restriction [4, 5]. METHODS: We present a 27-year-old female who underwent RYGB for morbid obesity. Two years post-surgery, she was referred to the ER due to tremor, palpitations, and syncope. On investigation, her capillary glucose was as low as 37 mg%. The hypoglycemic episodes repeated a few times a day. A comprehensive investigation included a 72 h fasting test, blood tests-serum C peptide and insulin, plasma sulfonylurea, anti-insulin ab, abdominal CT, MRI, octreotide test, and EUS. None of the tests showed any pathology, and she was given the diagnosis of PHH and was treated medically with diazoxide and acrabose without improvement. Surgical options were discussed with the patient and a conversion of the RYGB to sleeve gastrectomy was scheduled. RESULTS: In this video, we show how to revise an RYGB to treat PHH, by converting the RYGB to a sleeve gastrectomy. The intervention starts by restoring the normal anatomy of the small bowel with resection of the 100-cm Roux limb. Then, the greater curvature of the bypassed stomach was resected. A standard LSG around a 34Fr bougie was performed. A gastro-gastric anastomosis was fashioned between the pouch and the remnant stomach. The patient's operative and post-operative course was unremarkable with no further hypoglycemic episodes to date after 1-year follow-up. CONCLUSIONS: This technique was shown to be safe and effective as a part of the surgical treatment of post- bariatric PHH.

The use of Ursolit for gallstone prophylaxis following bariatric surgery: a randomized-controlled trial.

BACKGROUND: Although bariatric surgery (BS) predisposes patients to development of gallstone formation, a preventive strategy is still in debate. AIM: To compare the incidence of gallstone formation between patients treated with ursodeoxycholic acid (UDCA) vs. placebo for a duration of 6 months following BS. METHODS: This multicenter randomized, double-blind controlled trial entails treatment with UDCA vs. an identical-looking placebo. The primary outcome was gallstone formation, as measured by abdominal ultrasound. RESULTS: The data of 209 subjects were enrolled in the study, and 92 subjects completed the study and were analyzed (n = 46 for each study group). The high dropout rate was mainly due to difficulties in adding more medications and swallowing the pill. Among the subjects who completed the study, 77.2% were women, and their mean age and pre-surgery BMI were 42.2 ± 10.2 years and 44.4 ± 6.1 kg/m2, respectively. Gallstone formation was recorded in 45.7% (n = 21) vs. 23.9% (n = 11) of subjects among placebo vs. UDCA groups, respectively, p = 0.029. Subgroup-analysis, according to surgery type, found that the results were significant only for SG subjects (p = 0.041), although the same trend was observed for OAGB/RYGB. Excess Weight Loss percent (%EWL) at 6 months post-surgery was 66.0 ± 17.1% vs. 71.8 ± 19.5% for the placebo and UDCA groups, respectively; p = 0.136. A trend towards a reduction in prescribed comorbidity medications was noted within-groups during the follow-up period, as compared to baseline, with no between-group differences (p ≥ 0.246). Moreover, no between-group differences were found for blood test results (p ≥ 0.063 for all). CONCLUSION: Administration of UDCA significantly decreased gallstone formation at 6 months at following BS. CLINICALTRIALS. GOV NUMBER: NCT02319629.